Mopidralazine

This classification denotes an antihypertensive agent with the molecular formula C14H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96600S6GLK, chemically known as 4-(6-((2,5-dimethylpyrrol-1-yl)amino)-3-pyridazinyl)morpholine but generally known as mopidralazine, which bears US NIH Compound Identifier 71143. European Medicines Agency schedules Mopidralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09059MIG. The term MOPIDRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). MOPIDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mopidralazine under HS 29349990 and SITC 51579. As of Q4 2014, MOPIDRALAZINE remains the US FDA Preferred Term for this commodity. Mopidralazine bears US NLM identifiers UMLS ID C0066788 and NCI Concept Code C66191. SMILES: O1CCN(CC1)c1nnc(Nn2c(ccc2C)C)cc1.